An observational study in Multiple Myeloma, sponsored by Seoul National University Hospital. Status unknown at 1 site in South Korea. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Seoul National University Hospital · Observational
This prospective study aims to perform intra-individual comparison of the image quality between ultra-low-dose whole-body CT with deep learning reconstruction and conventional low-dose whole-body CT with iterative reconstruction in patients with suspected multiple myeloma.
3,713 studies on the registry are indexed under Multiple Myeloma; 752 are open to participants now.
This study's planned enrollment of 30 is below the median of 145 across 482 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Seoul National University Hospital is the lead sponsor of 1,898 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients who are referred to Hemoatooncology department with suspicion of multiple myeloma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with suspicion of multiple myeloma and scheduled for CT
Diagnostic Test: noncontrast-enhanced whole-body CT
noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation). * conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction * ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software.
Contrast-to-noise ratio
Contrast-to-noise ratio (CNR) of the vertebral body and paraspinal muscle obtained at L1 vertebra level
Time frame: 3 months after the CT scan
Noise
Noise at paraspinal muscle
Time frame: 3 months after the CT scan
Signal-to-noise ratio (SNR)
Signal-to-noise ratio (SNR) at paraspinal muscle
Time frame: 3 months after the CT scan
Edge rising distance
Edge rising distance at vertebral cortex
Time frame: 3 months after the CT scan
Subjective overall image quality
Subjective overall image quality on four-point scale (1: worst, 4: excellent, representative value is average score)
Time frame: 3 months after the CT scan
Conspicuity of bone structure
Conspicuity of bone structure on four-point scale (1: worst, 4: excellent, representative value is average score)
Time frame: 3 months after the CT scan
Conspicuity of soft tissue
Conspicuity of soft tissue on four-point scale (1: worst, 4: excellent, representative value is average score)
Time frame: 3 months after the CT scan
Lesion detectability
Myeloma lesion detection rate on conventional low-dose CT and ultra-low-dose CT by blinded reviewers
Time frame: 3 months after the CT scan
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2022 (actual). Primary completion is estimated for Dec 2022, 2 months after the start.
Of 175 non-industry observational studies under Multiple Myeloma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 33. This study's planned 2 months is below that.
Counting every sponsor, half of 238 studies reached it within 61 months; a quarter within 31 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →